Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Unit 1 St James Business Park Grimbald Crag Court Knaresborough HG5 8QB Our ref: MMT/AdvisoryNote/NSAIDs Date December 2016 To: Practice Prescribing Leads Practice Managers Re: NSAIDs Dear Colleague, For the December “Hints and Tips on Prescribing”, the Medicines Management Team would like to encourage practices to review patients who are prescribed NSAID preparations which do not have a good evidence base for their use or where there are more cost-effective alternatives. General advice If an NSAID is needed then prescribe the lowest dose for the shortest duration, e.g. ibuprofen ≤1200mg daily in divided doses) or naproxen (≤1000mg daily in divided doses). These are associated with a lower cardiovascular risk than other NSAIDs. Regularly review the appropriateness of NSAID prescribing, especially in people who are at higher risk of both gastrointestinal and cardiovascular and renal morbidity and mortality, e.g. older people. If a NSAID is needed, consider switching to a lower risk agent where appropriate. When prescribing a NSAID consider the need for PPI, especially if the patient is at high risk of a GI bleed, e.g. aged over 65, or on long term treatment with a NSAID. Enteric coated NSAIDs do not provide sufficient gastro protection. A non ec NSAID and a PPI should be used instead, if the patient is at risk of GI events. PPIs currently recommended HaRD are: Omeprazole 20mg od Lansoprazole 15 - 30mg od Enteric coated naproxen in HaRD CCG - 6months to Oct 2016 NSAIDs Monthly briefing/letter – Dec 16 Page 1 of 2 HaRD Medicines Management Team Action points Please check if any of the following are prescribed in your practice: Enteric coated naproxen - consider changing to plain naproxen with a PPI if necessary, as this is more cost-effective. NSAID / PPI combination products, e.g. Vimovo, as these are much more expensive than prescribing a NSAID and a PPI separately. Arthrotec 50 or Arthrotec 75 containing diclofenac and misoprostol. A PPI is recommended for gastroprotection for patients on a NSAID, (rather than misoprostol), and naproxen or ibuprofen are the preferred NSAIDs as they are associated with a lower thrombotic risk than other NSAIDs. Branded products of NSAIDs, e.g. Naprosyn, Voltarol SR, Voltarol dispersible, Voltarol ec, Diclomax SR, Diclomax Retard. Please prescribe generically. Diclofenac / misoprostol combinations in HaRD CCG – 6months to Oct 2016. Practice BEECH HOUSE SURGERY CHURCH AVENUE MEDICAL GROUP CHURCH LANE SURGERY DR AKESTER & PTRS DR INGRAM & PTRS EAST PARADE SURGERY EASTGATE MEDICAL GROUP KINGSWOOD SURGERY NIDDERDALE GROUP PRACTICE NORTH HOUSE SURGERY PARK PARADE SURGERY RIPON SPA SURGERY SPRINGBANK SURGERY STOCKWELL ROAD SURGERY THE LEEDS ROAD PRACTICE THE MOSS PRACTICE THE SPA SURGERY Total Items Total Cost 13 £187.14 6 £110.61 7 £124.81 0 £0.00 20 £266.09 3 £31.40 31 £367.37 11 £165.60 4 £58.63 1 £14.65 0 £0.00 20 £241.67 0 £0.00 7 £109.53 5 £73.76 26 £345.51 9 £127.18 163 £2,223.97 Our Prescribing Support Team is available to help practices with this work if required. HaRD versions of OptimiseRx and SystmOne and EMIS formularies will be amended to incorporate these recommendations. Local community pharmacies have been e-mailed to inform them that practices will be undertaking this switch. As the timings of the switch will vary between practices it is advisable that each practice notifies its local pharmacies in advance of the switch, to enable effective management of stock. Should you have any queries, recommendations or ideas about this or future initiatives then we would be pleased to hear from you. Yours sincerely, The Medicines Management Team, HaRD CCG. References 1. eBNF accessed 23.11.16 2. Department of Health Drug Tariff. Accessed on-line 23.11.16 3. NICE Key Therapeutic Topic NSAIDS Feb 2015. NSAIDs Monthly briefing/letter – Dec 16 Page 2 of 2 HaRD Medicines Management Team